Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis

Alberto Papi, David Price, Joaquin Sastre, Kirsten Kaiser, Mark Lomax, Tammy McIver, Sanjeeva Dissanayake

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


BACKGROUND: Fluticasone propionate and formoterol fumarate have been combined in a single inhaler (fluticasone/formoterol; flutiform(®)) for the maintenance treatment of asthma. This pooled analysis assessed the efficacy of fluticasone/formoterol versus fluticasone in patients who previously received inhaled corticosteroids.

METHODS: Data were pooled from five randomised studies in patients with asthma (aged ≥12 years) treated for 8 or 12 weeks with fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.; n = 528 delivered via pMDI) or fluticasone alone (100, 250 or 500 μg b.i.d.; n = 527).

RESULTS: Fluticasone/formoterol provided significantly greater increases than fluticasone alone in mean morning forced expiratory volume in 1 second (FEV1) from pre-dose at baseline to 2 hours post-dose at study end (least-squares mean [LSM] treatment difference: 0.146L; p < 0.001) and in pre-dose FEV1 from baseline to study end (LSM treatment difference: 0.048 L; p = 0.043). Compared with fluticasone, fluticasone/formoterol provided greater increases in the percentage of asthma control days (no symptoms, no rescue medication use and no sleep disturbance due to asthma) from baseline to study end (LSM treatment difference: 8.6%; p < 0.001), and was associated with a lower annualised rate of exacerbations (rate ratio: 0.71; p = 0.014).

CONCLUSIONS: In summary, fluticasone/formoterol provides clinically significant improvements in lung function and asthma control measures, with a lower incidence of exacerbations than fluticasone alone.

Original languageEnglish
Pages (from-to)208-217
Number of pages10
JournalRespiratory Medicine
Issue number2
Early online date3 Dec 2014
Publication statusPublished - Feb 2015

Bibliographical note

Copyright © 2014 Elsevier Ltd. All rights reserved.

The authors would like to thank colleagues at Mundipharma Research Limited (Cambridge, UK) who conducted the pooled analysis, and Oxford PharmaGenesis™ Limited (Oxford, UK) who provided medical writing services on behalf of Mundipharma Research Limited. Studies 1–4 were sponsored by Skyepharma (Muttenz, Switzerland). Study 5 was sponsored by Mundipharma Research Limited (Cambridge, UK).


  • asthma
  • combination therapy
  • efficacy
  • fluticasone propionate
  • formoterol


Dive into the research topics of 'Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis'. Together they form a unique fingerprint.

Cite this